Psilocybin Content in P. cubensis: The Analytical Chemistry

Psilocybin Species Research

0.1–2.4% psilocybin dry weight range

Across 150+ real-world P. cubensis samples, published analytical chemistry found psilocybin content ranging from 0.1% to 2.4% dry weight, a 24-fold variation within the same species.

Gotvaldová et al., International Journal of Molecular Sciences, 2022

5

distinct alkaloids identified in P. cubensis tissue

Penis Envy

strain confirmed significantly higher by LC-MS/MS analysis (Goff 2024)

First flush

typically the highest-potency harvest from a given substrate run

Gotvaldová et al., International Journal of Molecular Sciences, 2022

View as image ↗

Content note: Psilocybe cubensis is a Schedule I controlled substance in the United States and illegal in most jurisdictions. This article covers analytical chemistry and natural product pharmacology as scientific education. It does not provide cultivation guidance, acquisition guidance, or dosing recommendations.

When analytical chemists analyze P. cubensis samples across different sources, a recurring finding is how wide the natural variation in psilocybin content turns out to be. A 2022 analysis of over 150 samples found content ranging from 0.1% to 2.4% of dry weight, a 24-fold range within a single species.^[2] What drives that variation, what other alkaloids sit alongside psilocybin in P. cubensis tissue, and what the pharmacology shows about how they interact is covered by an expanding body of analytical research.

This article covers the published research on psilocybin content Psilocybe cubensis and the five alkaloids present in its tissue. For broader context on the species (taxonomy, biology, history, and named cultivar varieties), see the Psilocybe cubensis species overview.

The Published Numbers: 0.1-2.4% Dry Weight Across 150+ Samples

Gotvaldová and colleagues (2022) published the most comprehensive multi-source alkaloid analysis to date, analyzing 150+ samples from multiple Psilocybe species including P. cubensis.^[2] This dataset provides the most reliable published range for naturally occurring psilocybin content.

For P. cubensis specifically, psilocybin content ranged from 0.1% to 2.4% of dry weight. The distribution was not uniform; most samples clustered in the 0.37-1.3% range, with values at the extremes representing unusual samples (either very low or unusually high).

Source: Gotvaldová et al. (2022), with baeocystin pharmacology from Glatfelter et al. (2022) and Rakoczy et al. (2024)

These numbers come from samples analyzed by certified analytical methods, not from anecdotal community reports or estimated average values. The 24-fold variation between the lowest and highest values in the dataset is not statistical noise; it reflects genuine biological and environmental variation within the species.

Why the Same Species Shows 24-Fold Variation in Content

Several factors contribute to the wide psilocybin content range within P. cubensis:

Strain genetics. Named cultivar varieties of P. cubensis are phenotypic selections; cultivators have selectively propagated strains with particular appearance or yield characteristics. Analytical chemistry studies confirm that alkaloid content is partly heritable: the Penis Envy cultivar, for example, consistently shows higher psilocybin content than typical strains when measured by LC-MS/MS (discussed below). The genetic basis lies in variation within the psilocybin biosynthetic gene cluster. Different alleles of the PsiD, PsiK, PsiM, and PsiH enzyme genes produce different alkaloid ratios and absolute amounts.

Harvest timing. Bigwood and Beug (1982) published the original characterization of flush-to-flush variation in P. cubensis alkaloid content: the first harvest typically shows the highest psilocybin concentration, with measurable declines in subsequent harvests from the same substrate.^[4] This finding has been replicated and is broadly accepted in the analytical chemistry literature. The mechanism likely involves substrate nutrient depletion and the energetic cost of alkaloid biosynthesis.

Developmental stage. The ratio of psilocybin to psilocin changes as the fruiting body matures. Psilocin is the dephosphorylated form; it accumulates when alkaline phosphatase activity is higher and when tissue damage occurs. Very young or very mature specimens show different alkaloid profiles than specimens in the typical mid-development harvest window.

Storage conditions. Gotvaldová and colleagues (2021) specifically tested alkaloid stability in P. cubensis tissue and found a striking asymmetry: psilocybin retained over 95% of its original content after 6 months of storage under typical conditions, while psilocin degraded significantly under the same conditions.^[3] This is the evolutionary logic behind P. cubensis storing primarily psilocybin rather than psilocin. The phosphate group (the "pro-" in prodrug) provides both biological stability protection and chemical stability, as psilocybin is pharmacologically inactive until dephosphorylated.

Strain Variation: What LC-MS/MS Actually Measured

The gold standard for alkaloid quantification is liquid chromatography-tandem mass spectrometry (LC-MS/MS), which can identify and quantify multiple alkaloids simultaneously with high accuracy. Most published natural product chemistry work uses this method or related approaches.

Goff and colleagues (2024) applied LC-MS/MS directly to named P. cubensis cultivar strains to produce the most rigorous strain comparison data currently in the literature.^[1] The key finding: Penis Envy showed significantly higher psilocybin and psilocin content than typical strains in the analysis. This provides the first peer-reviewed analytical confirmation of the longstanding community belief that this cultivar is more potent.

What the data does not show: measured differences in experiential outcomes between strains. No clinical trial has administered specific P. cubensis strains and compared subjective effects in controlled conditions. The Goff 2024 data confirms the chemical difference; the experiential translation of that difference remains scientifically uncharacterized beyond what self-report surveys can provide.

The broader point is that "strain" in mycology works differently from "strain" in bacteriology or virology. Named P. cubensis cultivars are not genetically validated subspecies with standardized alkaloid profiles; they are phenotypic selections that retain variation between individual specimens. Even within a named cultivar, alkaloid content varies with growing conditions, substrate, flush number, and storage.

For a direct comparison of Golden Teacher, B+, and Penis Envy by appearance, genetics, and confirmed psilocybin content, see P. cubensis Strains Compared. For the broader named-variety landscape with over 100 documented cultivars, see P. cubensis Varieties: Golden Teacher, B+, Penis Envy, and More.

Beyond Psilocybin: The Five Alkaloids

P. cubensis produces five tryptamine alkaloids in measurable quantities. Understanding each requires looking at its individual chemistry and pharmacology rather than assuming they all behave like psilocybin.

Psilocybin is the primary alkaloid and the most analytically stable. It is pharmacologically inactive in the phosphorylated form and requires dephosphorylation by alkaline phosphatase (in the gut and liver) to become psilocin. The phosphate group also makes it water-soluble, which affects its distribution in tissue.

Psilocin is the active molecule: the dephosphorylated form that crosses the blood-brain barrier and binds directly to serotonin receptors. It is present in fresh tissue and can be measured analytically, but its instability means that dried samples often show lower psilocin content than the corresponding fresh specimens. The characteristic blue bruising reaction in P. cubensis is psilocin oxidizing on contact with air at the site of tissue damage. For the full biology of this reaction and how it relates to mushroom identification, see The Biology of Psilocybe cubensis.

Baeocystin is a closely related phosphorylated tryptamine, essentially N-methyl psilocybin with one fewer methyl group on the nitrogen. It is present in small amounts, typically less than 0.05% dry weight. Glatfelter and colleagues (2022) demonstrated that baeocystin produced head-twitch responses in mice (the behavioral proxy for psychedelic-like activity) at doses comparable to psilocybin, with similar 5-HT2A receptor binding affinity.^[5] This suggests baeocystin is pharmacologically active in its own right.

Norbaeocystin is present at trace levels and is the least pharmacologically characterized of the five. It has one fewer methyl group than baeocystin. Receptor binding data exists but in vivo behavioral evidence is limited.

Aeruginascin is structurally distinct: it's a quaternary ammonium compound rather than a tertiary amine. Rakoczy and colleagues (2024) found that aeruginascin attenuated (reduced) head-twitch responses in mice when co-administered with psilocybin, the opposite of baeocystin's additive profile.^[6] One proposed mechanism: aeruginascin may act as a 5-HT3 antagonist, blocking a different serotonin receptor that modulates the psychedelic response rather than activating it.

The Entourage Effect Debate: What the Pharmacology Shows

The "entourage effect" hypothesis (popular in both cannabis and psychedelic communities) proposes that minor alkaloids in whole-mushroom preparations meaningfully alter the effects compared to isolated psilocybin. The actual pharmacological evidence is more nuanced than the community narrative suggests.

The baeocystin data supports a version of the entourage hypothesis: Glatfelter 2022 shows this compound is active and could contribute to the overall alkaloid effect.^[5] If a sample contains both psilocybin and baeocystin at pharmacologically relevant concentrations, the combined effect plausibly differs from psilocybin alone.

The aeruginascin data complicates the simple additive narrative: Rakoczy 2024 shows this compound may dampen psychedelic-like activity, not amplify it.^[6] If aeruginascin attenuates effects, the whole-mushroom experience might actually be modulated downward relative to the psilocybin content alone, the opposite of what the simple entourage hypothesis would predict.

The honest current state: the alkaloid interaction data is preclinical, from animal models, and does not directly translate to human experiential claims. Whether the concentrations of minor alkaloids in typical P. cubensis specimens are high enough to produce pharmacologically meaningful modulation (given that they are present at trace levels and conversion efficiencies to active forms are not fully characterized) is not established. The entourage effect in P. cubensis is scientifically plausible, but not demonstrated. For a deep dive into this specific question, see the entourage effect in magic mushrooms.

The Bottom Line

Published analytical chemistry establishes that P. cubensis psilocybin content ranges from 0.1% to 2.4% dry weight, with most samples in the 0.37-1.3% range. Four additional alkaloids are present alongside psilocybin, and LC-MS/MS analysis has confirmed measurable strain-level differences, with Penis Envy showing significantly higher content than typical cultivars. The entourage effect hypothesis is supported for baeocystin (pharmacologically active and additive) but complicated by aeruginascin (which appears to attenuate rather than enhance psychedelic-like activity in animal models). The research base is growing but most pharmacological evidence remains preclinical.

Frequently Asked Questions

How much psilocybin is in dried magic mushrooms?

Published analytical chemistry on P. cubensis shows psilocybin content ranging from 0.1% to 2.4% dry weight, with most samples between 0.37% and 1.3% (Gotvaldová et al., 2022, n=150+ samples). This translates to roughly 1–13 mg psilocybin per gram dry weight in typical samples. Significant variation exists between strains, individual specimens, harvest flushes, and storage conditions.

What percentage of Psilocybe cubensis is psilocybin?

Typically 0.37–1.3% of dry weight in most samples, based on the largest published dataset (Gotvaldová et al., 2022, 150+ samples). Values below 0.1% and above 2.4% have been recorded but represent outliers. High-potency cultivars like Penis Envy show significantly higher percentages as confirmed by LC-MS/MS analysis (Goff et al., 2024).

Does psilocybin content vary between mushroom samples?

Yes, substantially: up to 24-fold within the same species. Key sources of variation: Key sources of variation: strain genetics, harvest flush number (first flush typically highest), developmental stage at harvest, substrate conditions, and storage (psilocin degrades significantly while psilocybin remains stable). Even within a named cultivar variety, individual specimens show variation.

What other alkaloids does Psilocybe cubensis contain?

Five tryptamine alkaloids have been identified: psilocybin (primary, most abundant and stable), psilocin (active form, less stable), baeocystin (trace, pharmacologically active per Glatfelter et al. 2022), norbaeocystin (trace, least studied), and aeruginascin (trace, may attenuate rather than add to psychedelic-like effects per Rakoczy et al. 2024).

Does drying affect psilocybin content in mushrooms?

Drying preserves psilocybin. Gotvaldová et al. (2021) found psilocybin retains over 95% of its content after 6 months of proper storage. Psilocin, the active metabolite, degrades significantly under the same conditions. This asymmetry is why dried specimens show relatively more psilocybin than psilocin compared to fresh tissue. The phosphate group in psilocybin provides chemical stability that psilocin lacks.

How much psilocybin is in one gram of Psilocybe cubensis?

At the typical midrange content (~0.6-1.0% psilocybin dry weight), one gram dry contains approximately 6-10 mg psilocybin. At 0.37% (lower typical range), approximately 3.7 mg/g. At 1.3% (upper typical range), approximately 13 mg/g. Higher-content strains like Penis Envy would exceed these values. These figures are analytical chemistry data from published studies, not dosing guidance.

Sources & References

1. 1RTHM-00879·Goff, Roman et al. (2024). “Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry..” Analytica chimica acta.Study breakdown →PubMed →↩
2. 2RTHM-00762·Gotvaldová, Klára et al. (2022). “Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids..” International journal of molecular sciences.Study breakdown →PubMed →↩
3. 3RTHM-00688·Gotvaldová, Klára et al. (2021). “Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis..” Drug testing and analysis.Study breakdown →PubMed →↩
4. 4RTHM-00003·Bigwood, J et al. (1982). “Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (Earle) Singer..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
5. 5RTHM-00759·Glatfelter, Grant C et al. (2022). “Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice..” ACS pharmacology & translational science.Study breakdown →PubMed →↩
6. 6RTHM-00901·Rakoczy, Ryan J et al. (2024). “Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms..” British journal of pharmacology.Study breakdown →PubMed →↩